Human Induced Pluripotent Stem Cells: Clinical Significance and Applications in Neurologic Diseases

Eun-Ah Chang, Sung-Won Jin, Myung-Hyun Nam, Sang-Dae Kim

Department of Laboratory Medicine, Korea University Ansan Hospital, Ansan, Korea
Department of Neurosurgery, Korea University Ansan Hospital, Ansan, Korea

The generation of human induced pluripotent stem cells (iPSCs) from somatic cells using gene transfer opens new areas for precision medicine with personalized cell therapy and encourages the discovery of essential platforms for targeted drug development. iPSCs retain the genome of the donor, may regenerate indefinitely, and undergo differentiation into virtually any cell type of interest using a range of published protocols. There has been enormous interest among researchers regarding the application of iPSC technology to regenerative medicine and human disease modeling, in particular, modeling of neurologic diseases using patient-specific iPSCs. For instance, Parkinson’s disease, Alzheimer’s disease, and spinal cord injuries may be treated with iPSC therapy or replacement tissues obtained from iPSCs. In this review, we discuss the work so far on generation and characterization of iPSCs and focus on recent advances in the use of human iPSCs in clinical setting.

Key Words: Cell-based therapy · Induced pluripotent stem cells · Precision medicine.

INTRODUCTION

Stem cells exhibit the capacity of self-renewal and may undergo differentiation into various tissue types. These are divided into pluripotent stem cells (PSCs; embryonic stem cells [ESCs] and induced pluripotent stem cells [iPSCs]) and multipotent stem cells (adult stem cells [ASCs]) based on their differentiation capacity. PSCs, including ESCs derived from embryos and iPSCs derived by gene transfer, may undergo indefinite proliferation and differentiate into different types of tissues depending on the treatment conditions. Multipotent stem cells, however, may be obtained from tissue-derived precursors (umbilical cord blood, bone marrow, adipose tissue, placenta, or blood), which are already grown tissues. Multipotent stem cells have only lineage-committed differentiation potential and may produce some cell types found within the particular tissue of origin (Fig. 1).

Of these stem cell types, iPSCs are derived from somatic cells by gene transfer in the presence of reprogramming factors. iPSCs face less ethical controversies than ESCs and are available for the development of new clinical applications and extending stem cell research to clinical setting. Scientific investigations involving iPSCs in developmental biology, pharmaco-toxicology, and molecular biology have been accel-
erated by novel technologies aimed specifically to improve iPSC generation, growth, modification, and monitoring\(^3,8,24,77\). At present, PSCs research has rapidly evolved to offer the possibility of replacing regenerated and non-regenerated tissues, including the heart, pancreas, and brain, and provide various cell types\(^37,90,96,97\). In particular, the field of regenerative neuroscience is very active and has already reached a clinical trial stages\(^4,37,33,83,94\). The following sections discuss the main stem cell types and sources used in research and clinical trials along with their applications.

**CELL TYPES AND SOURCES**

**Human ESCs**

Human ESCs are self-renewing pluripotent cells, and may produce cells from the three germ layers. These cells are derived from the donated embryos either from in vitro fertilization procedure or created by somatic cell nuclear transfer technique (Table 1). ESCs or the cells of the embryo that have not undergone modification for less than 14 days are called “omnipotent cells” or “pluripotent cells” owing to their ability to differentiate into all cell and tissue types that make up the

---

**Table 1.** Type of stem cells based on their differentiation capacities

<table>
<thead>
<tr>
<th>Differentiation capacity</th>
<th>Isolated cells</th>
<th>Origins &amp; methods</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multipotency</td>
<td>ASCs</td>
<td>Bone marrow, adipose tissue, umbilical cord, amniotic fluid, placenta, CNS</td>
<td>1. Less ethical concerns than ESCs and iPSCs</td>
<td>1. Less cell proliferation 2. Limit differentiation potential</td>
</tr>
</tbody>
</table>

ESCs : embryonic stem cells, US FDA : United States Food and Drug Administration, iPSCs : induced pluripotent stem cells, ASCs : adult stem cells, CNS : central nervous system.

---

Fig. 1. Isolation and characterization of pluripotent stem cells. ESC : embryonic stem cell, ICM : inner cell mass, iPSC : induced pluripotent stem cell, ASC : adult stem cell, CNS : central nervous system.
human body. In other words, these cells have the infinite ability to differentiate into all types of cells of the body\textsuperscript{45,81,86}.

Prior to 1998, scientists encountered difficulties in the isolation and cultivation of stem cells, as these cells present very short time during embryonic development and require special devices for their isolation from embryos. In 1998, however, a team of researchers led by Dr. James Thomson at the University of Wisconsin succeeded in isolating cells from the inner cell mass of blastocyst and cultivating human ESCs in a dish\textsuperscript{41}. Therefore, ESCs have greatly contributed to developmental biology and medicine. For instance, ESCs have facilitated the development of insulin-producing cells to treat diabetes\textsuperscript{86,98} or generation of neurons that can restore the function of patients paralyzed with spinal cord injuries\textsuperscript{16,20}. Many groups have demonstrated successful transplantation, survival, and differentiation of ESCs into neural cells in rodent models\textsuperscript{8,13,18,93}. In 2010, human ESC-derived oligodendrocyte progenitors were generated by Geron Corporation and a first-ever clinical trial involving patients with spinal cord injury (SCI) was performed\textsuperscript{17,75}. Advanced Cell Technology also reported a clinical trial using human ESC-derived retinal pigment epithelium to treat dry age-related macular degeneration in 2012\textsuperscript{21}. Despite these advantages, embryonic cells obtained from the fusion of sperm and egg may cause severe immune rejection when used in patient with DNA from allogenic embryonic cells which was not autologous\textsuperscript{5,12}. In addition, the use of human embryos may encounter ethical issues, which limit research and clinical applications. Therefore, it is necessary to develop new pluripotent cells that circumvent ethical or immunological problems\textsuperscript{15,86}.

### ASCs

ASCs are tissue-specific stem cells characterized with tissue-restricted differentiation. These cells have multipotency characteristics but lose pluripotency. ASCs are derived from the umbilical cord blood, bone marrow, adipose tissue, placenta, blood, or brain without direct use of embryo. These are primitive cells isolated just before undergoing differentiation into specific organs such as the bone, fat, cartilage, neuron, and blood. These include hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and neural stem cells (NSCs), all of which have become an important source for regenerative medicine\textsuperscript{27,45}.

The umbilical cord blood and bone marrow contain large number of HSCs and MSCs, including stromal cells. Adipose tissue is a source of MSCs, which have the potential to differentiate into blood cells, bone, fat, and cartilage\textsuperscript{27,30}. NSCs may be obtained from several regions of the fetal, postnatal, and adult central nervous system, including the subventricular zone of the brain and the spinal cord that may contain precursors for neurons, oligodendrocytes, and astrocytes\textsuperscript{38,45,64}.

ASCs have been extensively studied and are being tested in clinical trials for various diseases, including SCI\textsuperscript{16,17,30}. One of the important functions of ASCs is their anti-inflammatory and immunomodulatory effects and their ability to secret several neurotrophic factors; hence, ASCs may provide trophic support for endogenous and co-implanted cells\textsuperscript{34,15,47}. In addition, ASCs offer the advantage of avoiding less ethical debate than ESCs because these cells are isolated from the already-grown body tissues. However, ASCs tend to be difficult to proliferate and differentiate; hence, obtaining a desired cell shape or sufficient number of cells may be challenging\textsuperscript{27,25,30}.

### iPSCs

iPSCs were first developed by Yamanaka in 2006 using mice\textsuperscript{58}; human iPSCs were subsequently established in 2007\textsuperscript{76}. Since then, other researchers have developed human iPSCs and confirmed the reproducibility of the Yamanaka's research technique, a globally approved technology\textsuperscript{2,14,58,92}. iPSCs are derived from somatic cells of the adult body through the expression of specific exogenous genes or proteins and resemble ESCs morphologically, antigenically, and phenotypically in many ways. iPSCs have the following similarities as compared to ESCs derived from blastocysts\textsuperscript{45,74,77,86}: 1) the shape of the cell (round shape, large nucleus, and phosphorus, little cytoplasm) and the speed of growth are similar. 2) Gene expression and chromatin modification patterns are similar. 3) It may form teratoma in immunodeficient mice. 4) It produces chimera mouse upon insertion into a mouse blastocyst. And 5) germ line transmission of genes is possible.

Unlike ESCs, iPSCs have been generated from the tissues with somatic cells, such as the skin, dental tissue, peripheral blood, and urine. Thus, generation of iPSCs showed less ethical problems than ESCs and offers the advantage of customized treatment using the somatic cells of the patient with characteristics same as ESCs\textsuperscript{9,19,25,80,82,90}.

Yamanaka’s team successfully induced pluripotency in adult somatic cells using four retrovirally transfected tran-
scription factors, namely, Octamer 3/4 (Oct3/4), SRY-box containing gene 2 (Sox2), Krüppel-like factor 4 (Klf4), and the protooncogene cytoplasmic Myc protein (c-Myc), in fibroblasts (Fig. 2)\textsuperscript{76,78}. However, the retroviral infection technology that delivers each of the “Yamanaka factors” (Oct3/4, Sox2, Klf4, and c-Myc; reprogramming factors; first generation method) has two disadvantages for clinical applications. First, genomic integration of reprogramming factors may lead to unwanted effects such as tumorigenesis\textsuperscript{5,25,55}. Second, this technology may lead to impairment of pluripotency. Reprogramming factors are required to establish pluripotency, but continual activation of exogenous reprogramming factors may decrease the differentiation capacity into specific cell types or transform cells altogether\textsuperscript{44,92}.

Therefore, alternative induction methods have been introduced to avoid direct alterations of host cell DNA. The pluripotency genes either remain separate from the host genome or may be completely removable\textsuperscript{21,80}. For instance, to involve the transient expression of reprogramming factors or virus-free, using adenoviruses\textsuperscript{99}, plasmids\textsuperscript{64}, minicircle vectors\textsuperscript{60}, episomal vectors\textsuperscript{61,91}, synthetic mRNAs\textsuperscript{84} or recombinant proteins\textsuperscript{95} were developed (Fig. 3). iPSC reprogramming technology has been recently introduced to improve safety and increase efficiency through chemical approaches with small molecules\textsuperscript{39,41}. This new generation protocol may help achieve more controllable reprogramming than that induced by transcription factors. These advancements have enabled the use of iPSCs for therapeutic purposes\textsuperscript{5,40,43,63,90}.

Many research groups have studied the differentiation potential of iPSCs into three germ layers in humans for clinical applications\textsuperscript{3,11,37,90,98}. Human iPSCs use the same transcription network as ESCs, with similar early cell fate control mechanisms\textsuperscript{43,86}. For clinical applications, many specific lineage-committed cell types are required for cell therapy; these may be generated through good manufacturing practice conditions\textsuperscript{82}. The production of specific cell subtypes for therapy may necessitate specific culture conditions. These differences between the trophic responses in vitro and in vivo pose major challenges to the clinical translation of preclinical iPSC studies\textsuperscript{43,66,74}.

iPSCs may be used for the following applications: 1) development of disease-specific autologous cell therapy, 2) disease models to evaluate underlying mechanisms, and 3) drug screening and toxicity tests\textsuperscript{33,43,53,66,74,97}. However, as the history of iPSC research is short, the studies must be adequately verified to confirm the safe application of these cells for cell thera-
In addition, human iPSCs derived from the somatic tissue of living donors and human tissue harvesting require extensive ethical and legal considerations regarding the dissemination of results and potential commercial benefit to donors for clinical translation; hence, standard regulations and policies need to be established.

**Therapeutic Potential of Induced Pluripotent Stem Cells in Neurologic Diseases**

The use of iPSCs for clinical applications requires the avoidance of genetic vectors or transgenes, which pose unknown risks in humans. In recent years, commercial stem cell research laboratories focus on using Sendai virus or episomal reprogramming instead of transgenes. Several different sources and types of cells have been extensively evaluated in basic science and at preclinical stage for neurologic diseases. Dopaminergic neurons derived from non-human primate iPSCs have been successfully used to cure Parkinson’s disease. The generation of iPSC models from familial cases of Parkinson’s disease has greatly contributed to defining several molecular mechanisms related to disease progression. Another example is stem cell transplantation for SCI that offers promising therapeutic strategies to address the multifactorial nature of SCI. Transplanted neurospheres from human iPSCs into SCI mouse models were successful and showed no tumorigenesis. In addition, safe and effective engraftment of human iPSC-derived neural progenitor cells for SCI therapy has been confirmed in non-human primates.

**Combination with New Culture Technologies for Cell Therapy**

Advances in stem cell technology allow ESCs and iPSCs to exhibit unlimited proliferation properties, and the resulting cell differentiation reflects key structural and functional properties of organs such as the kidney, lung, gut, brain, and heart. During development, cell morphology and physiology undergo changes in terms of a wide variety of factors, and the culture environment plays a fundamental role in the growth of cells in cultures. Researchers started with two-dimensional (2D) approach by growing sheets of cells, but the use of three dimensional (3D) techniques or nano-topography such as culturing cells on 3D scaffolds (organoids) or Nano-Petri dishes is now common. 3D culture techniques with stem cells may provide various different type of organoids, and highlight information on the pathophysiology of diseases and the possible implications of therapy in clinical setting. In particular, organoid tissue culture may serve as a useful tool for modeling neurodevelopmental disorders such as microencephaly related with the exposure of Zika virus, as well as nanopatterned scaffolds for neural tissue engineering. Recent progress in stem cell biology, combined with basic knowledge of brain development, has led to a 3D culture method that recapitulates brain development in vitro. Human PSCs-derived 3D structures, referred to as ‘brain organoids’, have the potential to shed light on key aspects of development, moreover, patient-derived brain organoid may predict drug response in a personalized fashion. As a new technology, 3D bioprinting allows creation of a precisely controlled 3D tissue or organ through evaluation of cell localization with biomolecules that are almost similar to tissue-specific extracellular microenvironment. Thus, the synergism of stem cell biology and 3D-biomaterial technology being influential in iPSC-based research and translation. Recent advances in bio-inks, printable hydrogels that encapsulate living cells, have improved the outcome of 3D tissue/organ printing constructs. For instance, 3D bio-printed cardiac patches, articular bones and cartilages, or glioma cell-laden scaffolds have been developed. Therefore, the combination of 3D scaffolds with 3D bio-printing technologies may support the appropriate cellular microenvironment, including cell survival and proliferation, and integrate well into the host tissue. However, applications of 3D bioprinting include the generation of...
multilayered skin, bone, vascular grafts, heart valves need to be improved with respect to the mechanical strength and integrity in the manufactured constructs. A better understanding of the tissue/organ microenvironment, which consists of multiple types of cells, is imperative for successful 3D bioprinting. These approaches may serve as a major contributing factor for the regeneration or restoration of tissues/organs. The many potential applications of these techniques are only at the beginning of the exploration. Safe iPSC-derived 3D bio-printed tissues/organs will be soon constructed and used for cell therapy.

CONCLUSION

Regenerative medicine using human PSCs is at the peak of development and the expectations for the use of PSCs to treat incurable diseases are high. iPSC research has rapidly progressed and reached clinical applications, while the outcomes are expected to meet the requirement in the near future. The possibility of using iPSCs in regenerative medicine may circumvent the ethical problems associated with ESC usage; however, ESCs and iPSCs exhibit a common problem: prevention of tumor development that may occur in response to the complete differentiation of stem cells before transplantation. There is a risk of tumor development in this process and incidence of cancer has been reported in an animal experiment. However, attempts have been directed to overcome this issue, and researchers have employed small molecule materials, protein preparations, or viral integration-free iPSCs to create stable iPSCs. These solutions may play key roles in the commercialization of methods involving de-differentiation induction. There are many discussions on the standardization of PSCs for research and therapy, including cell line derivation, registries, characterization, storage, banking, distribution, and cell engineering. Therefore, the safety associated with the use of iPSCs needs to be continuously evaluated.

Efforts have been directed to treat rare and incurable diseases, and clinical research and treatment using stem cells have recently been extended to strengthen national strategic investment in advanced countries. It is also actively promoting the marketability of stem cell therapy drugs. Overcoming issues such as limited commercialization, inconsistent large-scale production, and safety issues of human iPSCs may allow researchers to provide a truly viable alternative cell therapy source. It would be possible to manage different pharmacological and genetic approaches that may provide new therapeutic strategies. In addition, patient-specific, disease-related cells may serve as an incredibly powerful tool for studying disease mechanisms through functional analysis, genetic alterations, and in vitro drug screening.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

INFORMED CONSENT

This type of study does not require informed consent.

AUTHOR CONTRIBUTIONS

Conceptualization: EAC, SDK
Data curation: EAC, MHN
Formal analysis: SWJ
Funding acquisition: SDK
Methodology: EAC, SWJ
Project administration: EAC, SWJ, MHN, SDK
Visualization: MHN, SDK
Writing - original draft: EAC
Writing - review & editing: EAC, SDK

Acknowledgements

This research was supported by the Korea University Medical Center (K1613701).

References


https://doi.org/10.3340/jkns.2018.0222


